COVID-19 vaccination status and willingness for further booster doses among staff and students of a tertiary care institute
DOI:
https://doi.org/10.47203/IJCH.2025.v37i04.011Keywords:
COVID-19 Vaccine, Booster Vaccine, Vaccine AcceptanceAbstract
Background: Vaccination remains the mainstay of COVID-19 prevention. While initial vaccine acceptance was high among healthcare workers (HCWs), the emergence of new variants and waning immunity necessitated vaccine boosters. The study aimed to ascertain the COVID-19 vaccination status of the staff and medical students of a tertiary care institute and their willingness for further booster doses. Methods: An observational study was conducted among healthcare workers (doctors, nurses, technicians), ancillary staff, and students. An online semi-structured questionnaire collected information from participants regarding sociodemographic characteristics, history of COVID-19 vaccination, acceptance and uptake of booster dose, and reasons for willingness to uptake booster. The Chi-square test assessed the association between sociodemographic variables and booster acceptance. Results: About 302 people filled the survey questionnaire. Most of the participants belonged to the 18-29 year age group (61.3%) and worked in the clinical departments (54.3%). The majority of them had received the Covishield vaccine (71.5%). Half of them had already received a COVID-19 booster. Seven out of ten participants were willing to uptake further vaccine booster. Being a healthcare worker and working in non-clinical department was significantly associated with booster acceptance. The perception of the COVID-19 vaccine as an immunity booster was a key motivator. About 15.1% of participants expressed a preference for a nasal booster for its convenience in administration. Conclusion: The study highlights a high willingness for COVID-19 vaccine boosters among healthcare professionals and medical students. It emphasizes the importance of continuous efforts to promote vaccine boosters, given the crucial role of the medical community in shaping public perception.
Downloads
References
Ministry of Health and Family Welfare. Press Statement by the Drugs Controller General of India (DCGI) on Restricted Emergency approval of COVID-19 virus vaccine [Internet]. Press Information Bureau. 2021 [cited 2025 Aug 25]. Available from: https://pib.gov.in/PressReleseDetail.aspx?PRID=1685761
Government of India. PM Launches pan India rollout of COVID-19 vaccination drive [Internet]. Press Information Bureau. 2021 [cited 2025 Aug 25]. Available from: https://pib.gov.in/Pressreleaseshare.aspx?PRID=1689021
Padhi BK, Chakrapani V, Gupta M, Sharma N, Patro BK, Kar SS, et al. Trends in willingness to receive COVID-19 vaccines among healthcare workers in India: Findings from repeated cross-sectional national surveys. Front Public Heal. 2022;10:994206.
Chakraborti S, Gill J, Goswami R, Kumar S, Chandele A, Sharma A. Structural Profiles of SARS-CoV-2 Variants in India. Curr Microbiol. 2023;80(1):1.
Selvavinayagam ST, Yong YK, Joseph N, Hemashree K, Tan HY, Zhang Y, et al. Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants. Front Public Heal. 2022;10:1018399.
World Health Organization. Interim statement on the use of additional booster doses of Emergency Use Listed mRNA vaccines against COVID-19 [Internet]. 2022 [cited 2025 Aug 25]. Available from: https://www.who.int/news/item/17-05-2022-interim-statement-on-the-use-of-additional-booster-doses-of-emergency-use-listed-mrna-vaccines-against-covid-19
Ministry of Health and Family Welfare. Guidelines for COVID-19 vaccination of children between 15-18 years and precaution dose to HCWs, FLWs & 60+ population with comorbidities. 2022.
Sharma N, Basu S, Lalwani H, Rao S, Malik M, Garg S, et al. COVID-19 Booster Dose Coverage and Hesitancy among Older Adults in an Urban Slum and Resettlement Colony in Delhi, India. Vaccines. 2023;11(7):1177.
Klugar M, Riad A, Mohanan L, Pokorná A. COVID-19 vaccine booster hesitancy (VBH) of healthcare workers in czechia: National cross-sectional study. Vaccines. 2021 Dec 1;9(12):1437.
Alhasan K, Aljamaan F, Temsah MH, Alshahrani F, Bassrawi R, Alhaboob A, et al. COVID-19 Delta Variant: Perceptions, Worries, and Vaccine-Booster Acceptability among Healthcare Workers. Healthcare. 2021;9(11):20.
Yadete T, Batra K, Netski DM, Antonio S, Patros MJ, Bester JC. Assessing Acceptability of COVID-19 Vaccine Booster Dose among Adult Americans: A Cross-Sectional Study. Vaccines. 2021;9(12):1424.
Rahi M, Yadav CP, Ahmad SS, Nitika, Das P, Sharma S, et al. Vaccination coverage and breakthrough infections of COVID-19 during the second wave among staff of selected medical institutions in India. PLOS Glob Public Heal. 2023;3(4):e0000946.
Tyagi K, Ghosh A, Nair D, Dutta K, Singh Bhandari P, Ahmed Ansari I, et al. Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India. Diabetes Metab Syndr. 2021;15(3):1007.
Krishna E, Karthikeyan V, Ahmad S, Ranjan A, KM AH, Pandey S, et al. Acceptance of Annual Booster Doses of COVID-19 Vaccines Among Indian Healthcare Professionals: A Pan-India Cross-Sectional Survey. Cureus. 2023;15(11):e49363.
Wu F, Yuan Y, Deng Z, Yin D, Shen Q, Zeng J, et al. Acceptance of COVID?19 booster vaccination based on the protection motivation theory: A cross?sectional study in China. J Med Virol. 2022;94(9):4115.
Jairoun AA, Al-Hemyari SS, El-Dahiyat F, Jairoun M, Shahwan M, Al Ani M, et al. Assessing public knowledge, attitudes and determinants of third COVID-19 vaccine booster dose acceptance: current scenario and future perspectives. J Pharm Policy Pract. 2022 15(1):1–13.
Rose W, Raju R, Babji S, George A, Madhavan R, Leander Xavier JV, et al. Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study. Lancet Reg Health Southeast Asia. 2023;12:100141.
Focosi D, Maggi F, Casadevall A. Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence. Viruses. 2022;14(2):187.
Slamanig S, González-Domínguez I, Chang LA, Lemus N, Lai TY, Martínez JL, et al. Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice. EBioMedicine. 2024;105:105185.
Declercq J, Gerlo S, Van Nevel S, De Ruyck N, Holtappels G, Delesie L, et al. Repeated COVID-19 mRNA-based vaccination contributes to SARS-CoV-2 neutralizing antibody responses in the mucosa. Sci Transl Med. 2024;16(770):eadn2364.
Harris E. NIH Starts Testing Nasal COVID-19 Vaccine in US. JAMA. 2024;332(8):610–610.
Lasrado N, Rowe M, McMahan K, Hachmann NP, Miller J, Jacob-Dolan C, et al. SARS-CoV-2 XBB.1.5 mRNA Booster Vaccination Elicits Limited Mucosal Immunity. Sci Transl Med. 2024;16(770):eadp8920.
Wang Q, Guo Y, Bowen A, Mellis IA, Valdez R, Gherasim C, et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe. 2024;32(3):315.
Anderer S. FDA Approves Updated COVID-19 Vaccines. JAMA. 2024;332(15):1228–1228.
Centers for Disease Control and Prevention. Staying Up to Date with COVID-19 Vaccines COVID-19 CDC [Internet]. 2025 [cited 2025 Aug 25]. Available from: https://www.cdc.gov/covid/vaccines/stay-up-to-date.html
Downloads
Published
How to Cite
License
Copyright (c) 2025 Meenal Madhukar Thakare, NIKITA SHARMA, Sunidhi Karol

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
